Premium
Impact of surgical staging in locally advanced cervical cancer and subsequent chemotherapy
Author(s) -
Marana Heitor Ricardo Cosiski,
de Andrade Jurandyr Moreira,
dos Reis Francisco José Cândido,
Tiezzi Daniel Guimarães,
Zola Fábio Eduardo,
Clagnan Willan Simões,
Garieri Alexandre Pavan
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21360
Subject(s) - medicine , cervical cancer , chemotherapy , radiation therapy , lymph node , surgery , dissection (medical) , cohort , carcinoma , cancer , radiology
Background Surgical staging (SS) is the gold standard for determination of the true extent of a patient's disease and is an important prognostic factor in cervical cancer. We investigated whether lymph node dissection (LND) prior to chemotherapy (CT) followed by radical surgery (RS) could modified overall (OS) and disease‐free survival (DFS). Methods We performed a cohort analysis of 98 patients with cervical carcinoma. The experimental group consisted of 36 patients who underwent SS followed by neoadjuvant chemotherapy, and then by RS (objective response) or chemo‐radiation therapy (with or without subsequent surgery when not possible). The control group consisted of 62 similarly treated patients without pretreatment SS. The value of this procedure as a diagnostic tool in defining the extent of disease was evaluated. Furthermore, LND/CT‐associated treatment complications and the impacts on OS and DFS were also evaluated. Results Fourteen (38.9%) patients had pelvic LN metastases and three (8.3%) patients had pelvic and para‐aortic LN metastases. The 39‐month OS and DFS rates for the current study were 80.6% for the staged group and 52% for non‐staged treatment ( P < 0.001). Conclusion SS in cervical cancer is a feasible and safe pretreatment procedure, and when associated with CT, it improves OS and DFS. J. Surg. Oncol. 2009;100:505–510. © 2009 Wiley‐Liss, Inc.